{
    "clinical_study": {
        "@rank": "66949", 
        "arm_group": [
            {
                "arm_group_label": "TRAVATAN", 
                "arm_group_type": "Experimental", 
                "description": "Travoprost 0.004% ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad\u00ae preservative, one drop to the study eye(s), once a day in the evening, for 6 months"
            }, 
            {
                "arm_group_label": "LUMIGAN", 
                "arm_group_type": "Active Comparator", 
                "description": "Bimatoprost 0.01% ophthalmic solution containing benzalkonium chloride (BAK),  one drop to the study eye(s), once a day in the evening, for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is evaluate effects of Travatan versus Lumigan on intraocular\n      pressure (IOP) and ocular surface and inflammatory biomarkers."
        }, 
        "brief_title": "An Efficacy and Tolerability Study of TRAVATAN\u00ae Versus LUMIGAN\u00ae", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with either open-angle glaucoma or ocular hypertension in at least one eye\n             and be treatment na\u00efve to any glaucoma treatment.\n\n          -  Intraocular pressure (IOP) between 19 mmHg and 35 mmHg in at least one eye, which\n             would be the study eye.\n\n          -  IOP considered to be safe (in the opinion of the investigator), in both eyes, in such\n             a way that should assure clinical stability of vision and the optic nerve throughout\n             the study period.\n\n          -  Able to follow instructions and be willing and able to attend all study visits.\n\n          -  Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each\n             eye.\n\n          -  Must read, sign, and date an Ethics Committee-approved informed consent form.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Known medical history of allergy, hypersensitivity or poor tolerance to any\n             components of the study medications to be used in this study that is deemed\n             clinically significant in the opinion of the Principal Investigator.\n\n          -  Any abnormality preventing reliable applanation tonometry in either eye.\n\n          -  Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either\n             eye.\n\n          -  Prior treatment of dry eye with punctal plugs, punctal cautery, Restasis\u00ae or topical\n             ocular corticosteroids.\n\n          -  History of ocular surface disease (dry eye) or current/prior use of dry eye\n             medications (either over-the counter or prescription medications).\n\n          -  Contact lens wear.\n\n          -  Intraocular conventional surgery or laser surgery in either eye that is less than\n             three months prior to the Screening Visit.\n\n          -  Use of any systemic medications known to affect IOP (e.g., oral beta-adrenergic\n             blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and\n             calcium channel blockers), which have not been on a stable course for at least 7 days\n             prior to Screening Visit or an anticipated change in the dosage during the course of\n             the study.\n\n          -  Women of childbearing potential not using reliable means of birth control, are\n             pregnant, or lactating.\n\n          -  Unwilling to risk the possibility of darkened iris or eyelash changes.\n\n          -  Participation in any other investigational study within 30 days prior to the\n             Screening Visit.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664039", 
            "org_study_id": "RDG-11-244", 
            "secondary_id": "2012-002078-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "TRAVATAN", 
                "description": "Travoprost 0.004% ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad\u00ae preservative, one drop to the study eye(s), once a day in the evening, for 6 months", 
                "intervention_name": "Travoprost 0.004% ophthalmic solution (TRAVATAN\u00ae)", 
                "intervention_type": "Drug", 
                "other_name": "TRAVATAN\u00ae"
            }, 
            {
                "arm_group_label": "LUMIGAN", 
                "description": "Bimatoprost 0.01% ophthalmic solution containing benzalkonium chloride (BAK),  one drop to the study eye(s), once a day in the evening, for 6 months", 
                "intervention_name": "Bimatoprost 0.01% ophthalmic solution (LUMIGAN\u00ae)", 
                "intervention_type": "Drug", 
                "other_name": "LUMIGAN\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Benzalkonium Compounds", 
                "Travoprost", 
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Glaucoma", 
            "Ocular hypertension"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center at 1-888-451-3937 for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessing the Efficacy and Tolerability of TRAVATAN\u00ae Solution Without BAK, Containing Polyquad\u00ae Preservative (Travoprost 0.004%) Versus LUMIGAN\u00ae 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Na\u00efve Patients With Ocular Hypertension or Open Angle Glaucoma", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Slovenia: Agency for Medicinal Products - Ministry of Health", 
                "Slovenia: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Change from Baseline in Intraocular Pressure (IOP) at 6 months", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Day 0), 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Ocular Hyperemia Grading at 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 0), 6 months"
            }, 
            {
                "measure": "Change from Baseline in Ocular Surface Disease Index at 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 0), 6 months"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}